Drug news
GW Pharma has statred a rolling submission at the FDA for Epidiolex (cannabidiol) to treat Dravet syndrome and Lennox-Gastaut syndrome.
GW Pharmaceuticals PLC,has announced it had started to submit a US NDA for its oral cannabidiol product Epidiolex in two epilepsy-related conditions, Dravet syndrome and Lennox-Gastaut syndrome. The submission should be completed by October 2017. An EU submission is expected in the fourth quarter of 2017.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.